Inferra AI / Company / AMRX
Amneal Pharmaceuticals, Inc.
AMRX · Health Care
Last earnings Jul 30, 2026
Key results
Net revenuequarter
$725 million
Net Revenue of $725 million
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Adjusted EPSquarter
$0.25
Adjusted Diluted EPS of $0.25
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Second Quarter 2025 Results Net revenue in the second quarter of 2025 was $725 million, an increase of 3% compared to $702 million in the second quarter of 2024.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Revenuequarter
23%
Specialty net revenue increased 23% driven by key branded products, including CREXONT , RYTARY and UNITHROID .
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Affordable Medicines net revenue increased 1% driven by strong performance of our complex product portfolio and new product launches, partially offset by supply timing.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AvKARE net revenue decreased 4% driven by growth in the government label sales channel offset by lower revenue in the distribution channel.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Net incomequarter
$22 million
was $22 million in the second quarter of 2025 compared to a net income of $6 million in the second quarter of 2024, reflecting higher revenue and gross profit.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Adjusted diluted earnings per share in the second quarter of 2025 was $0.25, an increase of 56%, compared to $0.16 for the second quarter of 2024.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AI analysis
Q2 2025 · reported Aug 5, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 5, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Net revenue | $725 million | — | — |
| Adjusted EPS | $0.25 | — | — |
| Revenue | 23% | — | — |
| Net income | $22 million | — | — |
Guidance · company-stated
Direction: Raised
“htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Q2 2025 Net Revenue of $725 million GAAP Net Income of $22 million Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million Adjusted Diluted EPS of $0.25 Raising 2025 Full Year Guidance Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 BRIDGEWATER, NJ, August 5, 2025 - Amneal Pharmaceuticals, Inc.”
“Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance.”
Classified from the release's primary full-year outlook statement.
Capital allocation
htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Q2 2025 Net Revenue of $725 million GAAP Net Income of $22 million Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million Adjusted Diluted EPS of $0.25 Raising 2025 Full Year Guidance Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 BRIDGEWATER, NJ, August 5, 2025 - Amneal Pharmaceuticals, Inc.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
Event summary
Second Quarter 2025 Results Net revenue in the second quarter of 2025 was $725 million, an increase of 3% compared to $702 million in the second quarter of 2024
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Q2 2025 Net Revenue of $725 million GAAP Net Income of $22 million Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million Adjusted Diluted EPS of $0.25 Raising 2025 Full Year Guidance Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 BRIDGEWATER, NJ, August 5, 2025 - Amneal Pharmaceuticals, Inc.”
Company outlook: “Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance.”
Revenue — Raised (“Raising”)
“htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Q2 2025 Net Revenue of $725 million GAAP Net Income of $22 million Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million Adjusted Diluted EPS of $0.25 Raising 2025 Full Year Guidance Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 BRIDGEWATER, NJ, August 5, 2025 - Amneal Pharmaceuticals, Inc.”
Company outlook — Raised (“raise”)
“Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance.”
Company outlook — Raised (“Raising”)
“Raising Full Year 2025 Financial Guidance The Company is raising its previously provided full year 2025 guidance.”
Classified from the release's primary full-year outlook statement.
Capital allocation
htm EX-99.1 Document Exhibit 99.1 AMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Q2 2025 Net Revenue of $725 million GAAP Net Income of $22 million Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million Adjusted Diluted EPS of $0.25 Raising 2025 Full Year Guidance Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 BRIDGEWATER, NJ, August 5, 2025 - Amneal Pharmaceuticals, Inc.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Finally, we are extremely pleased with the successful completion of our debt refinancing, which was oversubscribed multiple times and will yield substantial interest cost savings while extending maturities.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Updated Guidance Prior Guidance Net revenue $3.0 billion - $3.1 billion $3.0 billion - $3.1 billion Adjusted EBITDA (1) $665 million - $685 million $650 million - $675 million Adjusted diluted EPS (2) $0.70 - $0.75 $0.65 - $0.70 Operating cash flow $275 million - $305 million $255 million - $285 million Operating cash flow, excluding discrete items (3) $300 million - $330 million $280 million - $310 million Capital expenditures (4) Approximately $100 million Approximately $100 million 1 (1) Includes 100% of adjusted EBITDA from AvKARE.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
(4) Reflects estimated capital expenditures, net of expected contributions from an alliance partner of $20 million.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Debt Refinancing Optimizes Capital Structure On August 1, 2025, Amneal successfully completed a comprehensive debt refinancing.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The Company entered into $2.1 billion of new seven-year Term B loans at a rate of SOFR plus 350 basis points and issued $600 million aggregate principal amount of 6.875% senior secured notes due 2032.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Strategy & priorities
Amneal s 2025 estimates are based on management s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Forward-looking statements may be identified by the use of words such as plans, expects, will, anticipates, targets, estimates, and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; our strategy for growth; product development; regulatory approvals; market position and expenditures.
SEC original ↗Amneal Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company s filings with the Securities and Exchange Commission, including under Item 1A, Risk Factors in the Company s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K.
SEC original ↗Amneal Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Legal Proceedings 50 Item 1A.
SEC original ↗Amneal Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of our control.
SEC original ↗Amneal Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financial condition could vary materially from expectations and projections expressed or implied in our forward-looking statements.
SEC original ↗Amneal Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
government shutdown could adversely impact our regulatory, operational and financial performance; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties such as those described in Note 16.
SEC original ↗Amneal Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documentsEarnings releases
10 documentsPresentations
0 documentsNo presentations for Amneal Pharmaceuticals, Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Amneal Pharmaceuticals, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.